Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes

Type1diabetes Clinical Trial

— HypoADAPT  

Official title:

Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes - the HypoADAPT Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05095259
• Other study ID #: DRCMR7T-06
• Secondary ID: 2019-001938-34
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 16, 2019
• Est. completion date: December 2023

Study information

• Verified date: February 2023
• Source: Nordsjaellands Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An experimental mechanistic study. The overall objective is to gain new knowledge about mechanisms involved in adaptation to recurrent hypoglycaemia in diabetes by investigating patients with type 1 diabetes and healthy controls. The knowledge to be obtained may feed into experimental hypoglycaemic clamp studies to further elucidate the effect of the adaptations during acute hypoglycaemia. Ultimately, it may lead to intervention studies aiming at the maintenance of functional capability during hypoglycaemia in patients with type 1 diabetes to reduce their risk of severe hypoglycaemia.

Description:

Study rationale The risk of severe hypoglycaemia is a major daily concern for people with diabetes treated with insulin. Severe hypoglycaemia is the main barrier in achieving the recommended glycaemic targets and may indirectly be the main driver for late diabetic complications and related morbidity, mortality and health care costs. In people with diabetes, recurrent exposure to insulin-induced mild hypoglycaemia leads to significant adaptive physiologic responses. While the metabolism of the brain and hormonal responses to hypoglycaemia have been studied extensively, this study will as the first, systematically investigate the chronic adaptation of peripheral metabolism to recurrent hypoglycaemia in diabetes. Knowledge about such responses can lead to interventions that attenuate the devastating effects of acute hypoglycaemia induced by insulin in people with diabetes. Thereby, the risk of developing severe hypoglycaemia can be reduced which ultimately will improve long-term diabetes outcomes and reduce health care costs.

Hypothesis Patients with type 1 diabetes that are exposed to high-frequent recurrent hypoglycaemia will adapt their metabolism in a way, which supports the preservation of brain fuelling.

Objectives

Primary objective The overall objective is to gain new knowledge about mechanisms involved in adaptation to recurrent hypoglycaemia in diabetes by investigating patients with type 1 diabetes and healthy controls. The knowledge to be obtained may feed into experimental hypoglycaemic clamp studies to further elucidate the effect of the adaptations during acute hypoglycaemia. Ultimately, it can lead to intervention studies aiming at the maintenance of functional capability during hypoglycaemia in patients with type 1 diabetes to reduce their risk of severe hypoglycaemia.

Secondary objectives

• To study the metabolic consequences of recurrent hypoglycaemia in the brain, liver, muscle and adipose tissues

• To study the consequences of recurrent hypoglycaemia on resting metabolic rest

• To study the consequences of recurrent hypoglycaemia on glucagon and adrenaline sensitivity

• To study the consequences of recurrent hypoglycaemia on epigenetic profiles

• To study the consequences of recurrent hypoglycaemia on oxidative stress

• To study the psychological factors associated with recurrent hypoglycaemia

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Ability to provide written informed consent

2. Male or female aged 18-70 years

3. Must be able to speak and read Danish

4. Type 1 diabetes patients or healthy individuals (control goup)

5. A documented clinically relevant history of type 1 diabetes

6. In insulin treatment regimen

7. The subject must be willing and able to comply with trial protocol

Exclusion Criteria:

1. History of severe psychological condition

2. History of severe heart disease

3. History of epilepsy, former apoplexies and dementia

4. History of muscle diseases

5. History of liver disease

6. History of malignancy unless a disease-free period exceeding 5 years

7. Implants not compatible for MRI scans

8. History of alcohol or drug abuse

9. Pregnant or lactating woman

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Hypoglycemia
• Type1diabetes

Intervention

Drug:
• insulin human
Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of ~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
• Epinephrin
Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng·kg-1·min-1, 25 ng·kg-1·min-1 and 50 ng·kg-1·min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, ß-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.

Procedure:
• Muscle biopsy
With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( ~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
• Adipose tissue biopsy
With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( ~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.

Drug:
• Glucagon
Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, ß-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.

Device:
• IPRO 2 Medtronic Minimed
All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.

Procedure:
• 7 Tesla (7T) Magnetic Resonance Imaging
Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
• Indirect Calorimetry using Jaeger Oxycon Champion
Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
• Core temperature and thermography using Thermovision SC645
Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).

Device:
• Freestyle Libre 2
All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center Copenhagen	Gentofte
Denmark	Nordsjaellands Hospital	Hillerød

Sponsors (4)

Lead Sponsor	Collaborator
Nordsjaellands Hospital	Danish Research Centre for Magnetic Resonance, Steno Diabetes Center Copenhagen, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolite- and lipid profiling	Metabolite- and lipid profiling of blood samples using metabolomics profiling platforms during euglycaemia	5 minutes
Primary	Brain lactate concentration	Brain lactate concentration using non-invasive magnetic resonance (MR) spectroscopy during euglycaemia	20 minutes
Primary	Brain adenosine triphosphate (ATP) concentration	Brain ATP concentration using non-invasive MR spectroscopy during euglycaemia	20 minutes
Primary	Glycogen in muscle and adipose tissue	Glycogen in muscle and adipose tissue biopsies during euglycaemia	5 minutes
Primary	Non-specific proteins in muscle and adipose tissue	Non-specific proteins in muscle and adipose tissue biopsies during euglycaemia	5 minutes
Primary	Glycogen concentration	Glycogen in liver and muscle tissue using non-invasive MR spectroscopy during euglycaemia.	40 minutes
Secondary	Estimated glucose production during glucagon stimulation	Area under the curve (AUC) for plasma glucose during glucagon injections. Plasma glucose measurement	Every 5 minutes up to 5 hours
Secondary	Estimated glucose production during epinephrine stimulation	Area under the curve (AUC) for plasma glucose during epinephrine infusion. Plasma glucose measurement	Every 5 minutes up to 90 minutes
Secondary	Indirect calorimetry	Estimating resting metabolic rate, before and during hyperinsulinemic-hypoglycemic clamp	60 minutes
Secondary	Thermography	Estimating skin temperature, before and during hyperinsulinemic-hypoglycemic clamp	5 minutes
Secondary	Plasma lactate during glucagon injections.	Plasma lactate during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma free fatty acids during glucagon injections.	Plasma free fatty acids during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma glycerol during glucagon injections.	Plasma glycerol during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma alanine during glucagon injections.	Plasma alanine during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma ß-hydroxybutyrate during glucagon injections.	Plasma ß-hydroxybutyrate during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma insulin during glucagon injections.	Plasma insulin during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma glucagon during glucagon injections.	Plasma glucagon during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma metabolomics during glucagon injections.	Plasma metabolomics during glucagon injections.	Every 40 minutes up to 5 hours
Secondary	Plasma lactate during epinephrine infusion	Plasma lactate during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma free fatty acids during epinephrine infusion	Plasma free fatty acids during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma glycerol during epinephrine infusion	Plasma glycerol during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma alanine during epinephrine infusion	Plasma alanine during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma ß-hydroxybutyrate during epinephrine infusion	Plasma ß-hydroxybutyrate during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma insulin during epinephrine infusion	Plasma insulin during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma glucagon during epinephrine infusion	Plasma glucagon during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma epinephrine during epinephrine infusion	Plasma catecholamines during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma norepinephrine during epinephrine infusion	Plasma catecholamines during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Plasma metabolomics during epinephrine infusion	Plasma metabolomics during epinephrine infusion	Every 20 minutes up to 90 minutes
Secondary	Personality traits using the psychometry questionnaire Type D Scale-14 (DS-14)	Personality traits using the psychometry questionnaire DS-14, score between 0-28, the higher, the more likely they have type D personality	30 minutes
Secondary	Personality traits using the psychometry questionnaire Toronto Alexithymia Scale (TAS-20)	Personality traits using the psychometry questionnaire TAS-20, score 20-100, the higher score the more likely they are alexithymia	30 minutes
Secondary	Diabetes and hypoglycaemia status using psychometry questionnaire Hypoglycemia Fear Survey - Worry (HFS-W)	Diabetes and hypoglycaemia status using psychometry questionnaire HFS-W, score 0-72, the higher score the higher fear for hypoglycemia	30 minutes
Secondary	Diabetes and hypoglycaemia status using psychometry questionnaire Hypoglycemia Attitudes and Behavior Scale (HABS)	Diabetes and hypoglycaemia status using psychometry questionnaire HABS, score from 14-45, higher score more fear of hypoglycemia	30 minutes
Secondary	Diabetes and hypoglycaemia status using psychometry questionnaire Problem Areas in Diabetes (PAID)	Diabetes and hypoglycaemia status using psychometry questionnaire PAID, 0-80, the higher score, the more problems with diabetes	30 minutes
Secondary	Food consumption	Using Food Frequency Questionnaire to analyze food consumption	30 minutes
Secondary	Hypoglycemia awareness status	Using hypoglycemia awareness status questionnaire; , 0-7, higher score indicate hypoglycemia unawareness	10 minutes